Page last updated: 2024-12-10

sw033291

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SW033291: inhibits 15-hydroxyprostaglandin dehydrogenase (15-PGDH) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	3337839
CHEMBL ID	4061483
SCHEMBL ID	15525569
MeSH ID	M000607500

Synonyms (38)

Synonym
HMS1481P18
EU-0011111
CHEMDIV3_003164 ,
2-butylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[2,3-b]pyridin-3-amine
AKOS001635848
S7900
CS-4513
SCHEMBL15525569
HY-16968
AC-32909
sw033291
SR-01000489258-1
sr-01000489258
459147-39-8
mfcd02973087
EX-A632
sw-033291
2-(butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine
sw 033291
2-(butylsulfinyl)-4-phenyl-6-(2-thienyl)-thieno[2,3-b]pyridin-3-amine
AS-72360
sw033291, >=98% (hplc)
2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine
sw-033291;sw 033291
BCP15631
FT-0700311
us9789116, sw033291
bdbm347359
2-butylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[5,4-b]pyridin-3-amine
EN300-246041
SB19146
CHEMBL4061483 ,
CCG-268797
bdbm50266252
nsc-787269
nsc787269
2-(butylsulfinyl)-4-phenyl-6-(2-thienyl)-thieno[2,3-b]pyridine-3-amine
Z2213885911

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)	IC50 (µMol)	0.0022	0.0022	0.5750	2.7000	AID1482373
15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)	Ki	0.0001	0.0001	0.0001	0.0001	AID1482410; AID1918561
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Process	via Protein(s)	Taxonomy
kidney development	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
prostaglandin metabolic process	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
female pregnancy	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
parturition	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
lipoxygenase pathway	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
ovulation	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
response to estradiol	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
response to lipopolysaccharide	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
positive regulation of apoptotic process	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
response to ethanol	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
negative regulation of cell cycle	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
thrombin-activated receptor signaling pathway	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
ductus arteriosus closure	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
regulation of prostaglandin catabolic process	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Process	via Protein(s)	Taxonomy
prostaglandin E receptor activity	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
identical protein binding	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
NAD binding	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
NAD+ binding	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Process	via Protein(s)	Taxonomy
nucleoplasm	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
cytosol	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
basolateral plasma membrane	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
extracellular exosome	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
cytoplasm	15-hydroxyprostaglandin dehydrogenase [NAD(+)]	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1482384	Plasma concentration in CD1 mouse at 10 mg/kg, ip measured at 3 hrs post dose by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482382	Cmax in CD1 mouse at 10 mg/kg, ip measured at 10 to 1440 mins post dose by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482375	Inhibition of 15-PGDH in human A549 cells assessed as increase in IL-1beta-stimulated PGE2 levels at 2500 nM after 8 hrs by ELISA relative to DMSO	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482374	Inhibition of 15-PGDH in human A549 cells assessed as increase in IL-1beta-stimulated PGE2 levels at 20 nM after 8 hrs by ELISA relative to DMSO	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1918561	Binding affinity to 15-PGDH (unknown origin) assessed as inhibition constant	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.
AID1482373	Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NAD(+) by fluorescence assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482410	Inhibition of 15-PGDH (unknown origin) using PGE2 as substrate preincubated for 12 hrs followed by dialysis for 12 hrs and subsequent addition of NAD+ measured after 12 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482379	Half life in mouse liver S9 fractions at 2 uM in presence of NADPH by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482383	AUC in CD1 mouse at 10 mg/kg, ip measured at 10 to 1440 mins post dose by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482381	Protein binding in mouse plasma	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482377	Aqueous solubility of compound in pH 7 citrate buffer using amorphous form after 16 hrs by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1918539	Antifibrotic activity against bone marrow transplanted mouse model assessed as acceleration in peripheral blood neutrophils recovery at 5 mg/kg,ip bid measured by flow cytometry after 10 days post-transplant recovery period	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (31.25)	24.3611
2020's	11 (68.75)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	28.53 (24.57)
Research Supply Index	2.83 (2.92)
Research Growth Index	5.58 (4.65)
Search Engine Demand Index	31.58 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (28.53)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.21	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.62	7	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
bdp 12 1-(quinoxalin-6-ylcarbonyl)piperidine: modulates AMPA receptor desensitization ; an analog of 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine	2.41	1	N-acylpiperidine
Bardoxolone [no description available]	2.41	1	cyclohexenones
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	3.5	6	prostaglandins E	human metabolite; mouse metabolite; oxytocic
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	2.6	1	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
12-hydroxy-5,8,10-heptadecatrienoic acid 12-hydroxy-5,8,10-heptadecatrienoic acid: metabolite of arachidonic acid in blood platelet suspension; RN given refers to cpd without isomeric designation	2.6	1	hydroxy polyunsaturated fatty acid; long-chain fatty acid; trienoic fatty acid	metabolite

Condition	Relationship Strength	Studies
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Colitis Gravis [description not available]	2.41	1
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.41	1
Injury, Ischemia-Reperfusion [description not available]	2.41	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	7.41	1
Cancer of Colon [description not available]	2.41	1
Cancer of Liver [description not available]	2.41	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.41	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.41	1
Cirrhosis [description not available]	3.52	4
Cardiac Failure [description not available]	3.52	4
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	3.52	4
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	3.52	4
Sarcopenia Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.	2.6	1
Cryptogenic Fibrosing Alveolitis [description not available]	2.66	2
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	2.66	2
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Innate Inflammatory Response [description not available]	2.25	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.25	1
Age-Related Osteoporosis [description not available]	2.21	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.21	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.11	1

chemdatabank.com